Diabetic Nephropathy
Conditions
Interventions
Control:Patients with diabetes who met the inclusion criteria received standard hypoglycemic therapy and standard dose of ACEI or ARB therapy
Berberine treatment group:Patients with diabetes who met the inclusion criteria were treated with standard hypoglycemic therapy, standard dose of ACEI or ARB and berberine (0.5 g BID)
Positive drug group:Patients with diabetes who met the inclusion criteria were treated with standard hypoglycemic therapy, standard dose of ACEI or ARB, and oral dagaglizin (10mg QD)
Sponsors
First Hospital of Jilin University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Age =18 years old, gender is not limited; (2) Clinical diagnosis of diabetic nephropathy, blood glucose control standard (baseline level of glycosylated hemoglobin < 7.0%); (3) The degree of renal insufficiency was mild (eGFR<90ml/min/(1.73m²) but =60ml/min/(1.73m²) or urinary albumin/urinary creatinine (UACR) =30mg/g); (4) Berberine or daglizin treatment for patients whose subjects or their legal representatives have consented to the treatment and signed informed consent for the project.
Exclusion criteria
Exclusion criteria: (1) Patients with contraindications for berberine, ACEI/ARB or daglizin; (2) Newly diagnosed diabetic patients; (3) Those who have been judged by endocrinologists as having poor blood sugar control; (4) Pregnant or lactating women; (5) Patients with a history of using drugs to improve renal function (diuretics, glucocorticoids and proprietary Chinese medicines for protecting kidney, etc.) within the past 6 months; (6) Patients with anemia, severe liver insufficiency, infection or other diseases (such as malignant tumors, organ transplantation) or a history of drug abuse; (7) Patients with a life expectancy of less than 3 months or who are unable to complete the study for other reasons; (8) Unwilling to be followed up or poor treatment compliance; (9) are participating in other clinical investigators, or have participated in other clinical investigators within 3 months before enrollment, or have participated in this investigator; (10) Other conditions deemed unsuitable for inclusion by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Creatinine; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Urea Nitrogen;Blood Routine;Serum Lipid;Fingertip Blood Glucose;Glycosylated Hemoglobin; | — |
Countries
China
Contacts
Public ContactQian Tong
First Hospital of Jilin University
Outcome results
None listed